Sherry Pierce

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Hui Yang, Carlos E. Bueso‐Ramos, Courtney DiNardo et al. · Leukemia · 2013 · 670 citations · Full text

Hematological Malignancy, Bone Marrow Failure, Hematology +5

Effective Treatment of Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

Farhad Ravandi, E Estey, Dan Jones et al. · Journal of Clinical Oncology · 2008 · 373 citations · Full text

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 325 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

A prognostic score for patients with lower risk myelodysplastic syndrome

Guillermo Garcia‐Manero, J. Shan, S. Faderl et al. · Leukemia · 2007 · 316 citations

Hematological Malignancy, Bone Marrow Failure, Prognosis +5

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

Yasmin Abaza, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al. · Blood · 2016 · 293 citations · Full text